Discounted Cash Flow Calculation for BST:PUL using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for
is arrived at by discounting future cash flows to their present value using the 2 stage method. We use
analyst's estimates of cash flows going forward 5 years for the 1st stage, the 2nd stage assumes the company grows at a stable rate into perpetuity.
BST:PUL DCF 1st Stage: Next 5 year cash flow forecast
The current share price of
is above its future cash flow value.
Often investors are willing to pay a
for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Biosearch's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Biosearch has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare Biosearch's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Biosearch's earnings growth to the Germany market average as no estimate data is available.
Unable to compare Biosearch's revenue growth to the Germany market average as no estimate data is available.
Unable to determine if Biosearch is high growth as no earnings estimate data is available.
Unable to determine if Biosearch is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Biosearch's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
3/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
José María Roset Monrós
Mr. José María Roset Monros serves as the Chief Executive Officer of Biosearch SA (alternate name: Puleva Biotech SA) and served as its General Director. Mr. Monros served as the Chief Financial Officer of Puleva Biotech SA.
Insufficient data for José María to compare compensation growth.
Insufficient data for José María to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
José María Roset Monrós
Chief Executive Officer
Loreto Huertas De La Cámara
Chief Financial Officer
Alejandro Jara García Navas
Monica Olivares Martin
Santiago De La Escalera
Emma Madrid Sanchez-Gómez
Human Resources Director
David López Medina
Secretary of the Board of Directors
Ana María Moreno Jimenez
Food Safety & Quality Director
Antonio Martinez Descalzo
Jaime Lancha Fernández
Logistics & Purchases Director
Board of Directors Tenure
Average tenure of the
board of directors in years:
The tenure for the Biosearch board of directors is about average.
Biosearch, S.A., a biotechnology company, operates in pharmaceutical, nutraceutical, and functional food sectors in Spain and internationally. It offers a portfolio of approximately 200 products in lipids, probiotics, and botanical extracts. The company provides a range of probiotics isolated from human breast milk under the Hereditum brand for use in infant nutrition, gastrointestinal health, and immune system and prevention of infections. It also offers various eicosapentaenoic acid and docosahexaenoic acid rich ingredients under the Eupoly-3 name, which consists of oils, emulsions, and micro-encapsulated powder for functional foods, primarily dairy products, baby foods, medical foods, and food supplements. In addition, the company provides dry, fluid, glycerinated, and soft extracts under the Exxentia name. Biosearch, S.A. is headquartered in Granada, Spain.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.